Claritev appoints Jennifer Main to expanded board
Jennifer Main brings more than three decades of leadership experience across healthcare, technology, government and finance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Claritev Corporation increased its board from 11 to 12 directors on October 15, 2026, and appointed Jennifer Main as a Class II director and Audit Committee member. Concurrently, Jason Kap ceased serving as an Audit Committee member. Main will receive compensation under the company’s non-employee director compensation policy and enter into its standard form indemnification agreement.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Board size: 11 to 12 directors
Leadership experience: More than three decades
Healthcare payers served: More than 750
+3 more
6 metrics
Board size
11 to 12 directors
After the newly created directorship was added
Leadership experience
More than three decades
Jennifer Main’s experience across healthcare, technology, government and finance
Healthcare payers served
More than 750
Claritev company profile
Employers served
Over 100,000
Claritev company profile
Consumers served
60 million
Claritev company profile
Contracted providers
1.4 million
Claritev company profile
Key Terms
Class II director, non-employee director compensation policy, standard form indemnification agreement, Regulation FD
4 terms
Class II director regulatory
"to serve as a Class II director"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
non-employee director compensation policy financial
"in accordance with the Company's non-employee director compensation policy"
standard form indemnification agreement regulatory
"enter into the Company's standard form indemnification agreement"
Regulation FD regulatory
"to comply with Regulation FD"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What changed on CTEV’s board?
Claritev increased its board from 11 to 12 directors and appointed Jennifer Main as a Class II director and Audit Committee member, effective October 15, 2026. Concurrently, Jason Kap ceased serving as an Audit Committee member.
What experience does Jennifer Main bring to CTEV’s board?
Jennifer Main has more than three decades of leadership experience across healthcare, technology, government and finance. She served as Chief Operating Officer of the Centers for Medicare & Medicaid Services from 2018 to 2021 and as Chief Financial Officer of the Troubled Assets Relief Program at the U.S. Department of Treasury.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
(866 ) 909-7427
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Shares of Class A Common Stock, $0.0001 par value per share | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 15, 2026 (the "Effective Date"), Claritev Corporation (the "Company"), on the recommendation of the Nominating and Corporate Governance Committee of the Company's Board of Directors (the "Board"), increased the size of the Board from eleven (11) to twelve (12) directors. Effective as of the Effective Date, the Board appointed Ms. Jennifer Main to fill the newly created directorship, to serve as a Class II director and a member of the Audit Committee. Concurrently with Ms. Main's appointment to the Audit Committee, Mr. Jason Kap ceased serving as a member of the Audit Committee.
Ms. Main does not have a family relationship with any of our directors or executive officers and does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Ms. Main will receive compensation as a non-employee director in accordance with the Company's non-employee director compensation policy described in the section entitled "Compensation of Directors" of the Company's proxy statement filed with the Securities and Exchange Commission on March 20, 2026, and enter into the Company's standard form indemnification agreement.
Item 7.01 Regulation FD Disclosure.
On the Effective Date, the Company issued a press release announcing the appointment of Ms. Main to the Board. A copy of the press release is furnished as Exhibit 99.1 hereto.
The Company is furnishing the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, to comply with Regulation FD. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are included in this Form 8-K:
| 99.1 | Press Release dated October 15, 2026 | |||||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 15, 2026
Claritev Corporation
By: /s/ Douglas M. Garis
Name: Douglas M. Garis
Title: Executive Vice President and Chief Financial Officer
EXHIBIT 99.1
Claritev Appoints Jennifer Main to its Board of Directors
Board gains deep public sector healthcare and financial leadership expertise to support Claritev's growth strategy
McLean, VA — October 15, 2026 — Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of Directors (“Board”) has appointed Jennifer (Jenni) Main as a director, effective today, filling a newly created directorship on the Board. Main brings more than three decades of leadership experience across healthcare, technology, government, and finance. She currently serves as Chief Financial Officer of RealMDai (dba Certuma) and Overture Life, roles she has held since March 2026. Previously, she served as Chief Financial Officer and Chief Operating Officer of Amalgam Rx from 2021 to 2026.
“Jenni brings a valuable combination of financial leadership, healthcare experience, and public sector perspective,” said Travis Dalton, President and CEO of Claritev. “Her understanding of the healthcare ecosystem and experience leading through complex operating environments will be a strong asset to our Board as we continue to advance our strategy and deepen our impact across the industry.”
Main previously held several leadership roles at the Centers for Medicare & Medicaid Services (CMS), most recently serving as its Chief Operating Officer from 2018 to 2021. In that role, she oversaw operational execution across the agency's Medicare, Medicaid, and federal health insurance marketplace program, gaining firsthand insight into the regulatory and operational challenges facing payers, providers, and government healthcare programs.
Main also served as Chief Financial Officer for the Troubled Assets Relief Program (TARP) at the U.S. Department of Treasury, where she led the development and implementation of financial management services for the $700 billion program established in response to the 2008 financial crisis. Main holds a master’s degree in public policy from Harvard University and a bachelor’s degree in history from Cornell University.
“I’m excited to join the Board at such a pivotal moment in the company’s evolution,” said Main. “Claritev operates at the intersection of payers, providers, employers, and government, and its mission to make healthcare more affordable and transparent strongly resonates with me. I look forward to working with the Board and management team to help Claritev deliver even greater value to its clients and the patients they ultimately serve.”
About Claritev
Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders — including payers, employers, patients, providers, and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all.
Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.
Investor Relations Contacts
Todd Friedman
Head of Investor Relations and Strategic Communications
Claritev
investor@claritev.com
Media Relations Contact
Jen O'Connor
VP, Brand Marketing
Claritev
press@claritev.com
SOURCE: Claritev Corporation